Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva Pounces On US Revlimid Opportunity With Four Strength-Offering

Israeli Firm Has Partnered With Natco; December 2015 Settlement Provides For Entry

Executive Summary

Teva has bolstered its oncology offering in the US by moving first on one of the largest small-molecule opportunities in the US: Bristol Myers Squibb’s multi-billion-dollar blockbuster Revlimid (lenalidomide) to treat multiple myeloma.

You may also be interested in...



Cipla, Dr Reddy’s, Viatris And Teva Named In US Revlimid Antitrust Suit

Months after the first generic versions of Bristol-Myers Squibb’s multi-billion-dollar blockbuster Revlimid (lenalidomide) debuted in the US, indirect purchasers of the treatment for multiple myeloma have accused the originator and a raft of settling ANDA sponsors that their deals were anticompetitive.

Cipla Stays Upbeat On Advair Generic With ‘Superior’ Cost Position, Derisks Abraxane

Generic Revlimid and lanreotide propel Cipla’s US business to a high in the fiscal second quarter, with products like leuprolide depot set for debut ‘any time now’. Management signals cost edge for generic Advair as it awaits further word following a FDA establishment inspection report at its Indian site, while a Plan B is being initiated for generic Abraxane.

Blocked Pipeline Leads Teva’s US Generics To Fall Well Below $1bn Floor

Teva’s final quarterly earnings call of the year was indicative of its continued need to push valuable pipeline projects in the US to commercialization, as it once again lowered its full-year 2022 revenue guidance.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151705

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel